InsiderTrades.com logo
Blackrock’s Sending THIS Crypto Higher on Purpose
From Crypto 101 Media   |   Ad
It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…
YES, I WANT THE #1 CRYPTO NOW
Nadim Ahmed net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Nadim Ahmed Biography and Net Worth

Pres of Cullinan Therapeutics

Nadim Ahmed is the President and Chief Executive Officer of Cullinan Oncology.

Nadim has more than twenty-five years of leadership experience in oncology across a range of development and commercialization roles, including recently at Bristol Myers Squibb (BMS), where he served as President, Hematology and at Celgene Corporation (Celgene) where he served as President, Global Hematology & Oncology through its acquisition by BMS. As President, Hematology at BMS, Nadim oversaw multiple product launches and participated as a member of the company’s Leadership Team. Prior to BMS, Nadim served in leadership roles at Celgene across both development and commercialization functions. During this time at Celgene, he successfully launched multiple cancer medicines, including Pomalyst®, Abraxane® and several key indications for Revlimid®. Nadim has worked with various treatment modalities, including small molecules, biologics and cell therapy in hematology and solid tumors. Nadim holds a Master of Science degree from Loughborough University, UK and a Bachelor of Science degree from University College London, UK.

Nadim currently serves on the Board of Directors for Family Promise, a national non-profit organization helping homeless families.

How old is Nadim Ahmed?

Mr. Ahmed is currently 56 years old. There are 6 older executives and no younger executives at Cullinan Therapeutics. The oldest executive at Cullinan Therapeutics is Dr. Patrick A. Baeuerle Ph.D., Co-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board, who is 66 years old. Learn More on Nadim Ahmed's age.

How do I contact Nadim Ahmed?

The corporate mailing address for Mr. Ahmed and other Cullinan Therapeutics executives is , , . Cullinan Therapeutics can also be reached via phone at 617-410-4650 and via email at [email protected]. Learn More on Nadim Ahmed's contact information.

Has Nadim Ahmed been buying or selling shares of Cullinan Therapeutics?

Nadim Ahmed has not been actively trading shares of Cullinan Therapeutics during the past quarter. Learn More on Nadim Ahmed's trading history.

Who are Cullinan Therapeutics' active insiders?

Cullinan Therapeutics' insider roster includes Nadim Ahmed (Pres), Ansbert Gadicke (Director), Jennifer Michaelson (Insider), Jeffrey Trigilio (CFO), and Leigh Zawel (Insider). Learn More on Cullinan Therapeutics' active insiders.

Are insiders buying or selling shares of Cullinan Therapeutics?

During the last twelve months, insiders at the sold shares 14 times. They sold a total of 192,514 shares worth more than $3,567,594.66. The most recent insider tranaction occured on November, 5th when insider Jennifer Michaelson sold 8,000 shares worth more than $125,120.00. Insiders at Cullinan Therapeutics own 6.1% of the company. Learn More about insider trades at Cullinan Therapeutics.

Information on this page was last updated on 11/5/2024.

Nadim Ahmed Insider Trading History at Cullinan Therapeutics

See Full Table

Nadim Ahmed Buying and Selling Activity at Cullinan Therapeutics

This chart shows Mr. Nadim Ahmed's buying and selling at Cullinan Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cullinan Therapeutics Company Overview

Cullinan Therapeutics logo
Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $12.54
Low: $12.10
High: $12.78

50 Day Range

MA: $16.03
Low: $12.22
High: $18.15

2 Week Range

Now: $12.54
Low: $7.64
High: $30.19

Volume

479,037 shs

Average Volume

538,654 shs

Market Capitalization

$730.18 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
This Bull Market Indicator called NVDA at $116
From WealthPress   |   Ad
Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…
All you have to do is follow this link here